ZYBT vs CLPS

For growth investors, CLPS Incorporation (CLPS) is the stronger pick with 15.

2% revenue growth year-over-year, versus -12. 0% for Zhengye Biotechnology Holding Limited (ZYBT). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, CLPS Incorporation (CLPS) delivered a total return of -69.

3%, compared to -79. 9% for Zhengye Biotechnology Holding Limited (ZYBT). Over 10 years, the gap is even starker: CLPS returned -78. 6% versus ZYBT's -79. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CLPS Incorporation (CLPS) is the lower-risk stock at 0.

19β versus Zhengye Biotechnology Holding Limited's 1. 75β — meaning ZYBT is approximately 796% more volatile than CLPS relative to the S&P 500. On balance sheet safety, Zhengye Biotechnology Holding Limited (ZYBT) carries a lower debt/equity ratio of 25% versus 59% for CLPS Incorporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), CLPS Incorporation (CLPS) is pulling ahead at 15.

2% versus -12. 0% for Zhengye Biotechnology Holding Limited (ZYBT). Over a 3-year CAGR, CLPS leads at 2. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zhengye Biotechnology Holding Limited (ZYBT) is the more profitable company, earning 6.

1% net margin versus -4. 3% for CLPS Incorporation — meaning it keeps 6. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZYBT leads at 8. 8% versus -4. 0% for CLPS. At the gross margin level — before operating expenses — ZYBT leads at 49. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

All stocks in this comparison pay dividends.

CLPS Incorporation (CLPS) offers the highest yield at 14. 6%, versus 5. 3% for Zhengye Biotechnology Holding Limited (ZYBT).

For long-horizon retirement investors, CLPS Incorporation (CLPS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

19), 14. 6% yield). Zhengye Biotechnology Holding Limited (ZYBT) carries a higher beta of 1. 75 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CLPS: -78. 6%, ZYBT: -79. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ZYBT (Healthcare) and CLPS (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ZYBT is a small-cap income-oriented stock; CLPS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.